Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

By December 20, 2024

Enter Your Information Below To Receive Latest News, And Articles.
Your name

Your email
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!